Iridium photosensitizer constructed liposomes with hypoxia-activated prodrug to destrust hepatocellular carcinoma  

作　　者：Shuangling Luo Chao Liang Qianling Zhang Pingyu Zhang 

机构地区：[1]College of Chemistry and Environmental Engineering,Shenzhen University,Shenzhen 518060,China

出　　处：《Chinese Chemical Letters》2023年第4期110-115,共6页中国化学快报（英文版）

基　　金：the financial support of the National Natural Science Foundation of China (NSFC, Nos. 22077085, 22007104,22177078, 21907069);the Project of the Natural Science Foundation of Guangdong Province (No. 2019A1515011958);the Science and Technology Foundation of Shenzhen (Nos.JCYJ20210324095200002 and JCYJ20190808153209537)。

摘　　要：Hypoxic tumor microenvironment is a major challenge for photodynamic therapy(PDT). To overcome this problem, PDT combined hypoxia-activated chemotherapy is a promising strategy for hypoxic cancer therapy. Herein, a multifunctional liposome(AQ4N-Ir1-sorafenib-liposome) is prepared by encapsulating a hypoxia-activated prodrug AQ4N, a photosensitizer iridium(III) complex and hepatocellular carcinoma(HCC) targeting drug sorafenib, for synergistic therapy of HCC. Ir1-mediated PDT upon irradiation induces ROS generation and hypoxic environment, which leads to the disassembly of the liposome and activates the antitumor activity of AQ4N. Meantime, the co-delivered sorafenib could effectively target therapy of HCC. It is noted that ferroptosis mechanism is proved during the treatment. This work contributes to the design of hypoxia-responsive multifunctional liposome for combination of chemotherapy, targeting therapy and PDT. It is a promising strategy for hypoxic HCC therapy.

关 键 词：Hypoxia activation Iridium photosensitizer Ferroptosis Photodynamic therapy CHEMOTHERAPY 

分 类 号：R735.7[医药卫生—肿瘤]